Molecular Testing
-
April 27, 2020
The Challenges of Using Artificial Intelligence to Improve Cancer Treatment
With: Jeff Shrager, PhDRazelle Kurzrock, MDIn a previous post, CureMatch co-founder Razelle Kurzrock, MD, told us all about her company’s artificial intelligence (AI) platform that matches patients with treatments based on their cancer’s molecular profile. Here, AI expert Jeff Shrager, PhD, responds, and Kurzrock offers a rebuttal. Shrager is Co-Founder and Director of Research at xCures, and was formerly Director of Research at Cancer Commons. He is also an… Read more »
-
April 9, 2020
Molecularly Guided Therapy in Pancreatic Cancer: Untapped Potential and the ‘Bright Future’ Ahead Bookmark
George Lundberg, MDArticle from Medscape curated by Editor in Chief George Lundberg, MD, who notes:
Molecularly matched treatment for pancreatic cancer may extend life for some patients.
Go to full article published by Medscape.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
March 2, 2020
Using Artificial Intelligence to Match Combination Targeted Therapies in Oncology
With: Razelle Kurzrock, MDA Q&A with Razelle Kurzrock, MD, Director of the Center for Personalized Cancer Therapy and the Rare Tumor Clinic at U.C. San Diego, and Co-Founder and Board Member of CureMatch, Inc. Email: razelle@curematch.com Q: The new understanding of many cancers brought about by molecular testing has led to a whole new field: precision oncology, which emphasizes targeted and immunotherapy. While promising, and sometimes spectacularly… Read more »
-
February 21, 2020
Comprehensive Molecular Testing Needed for Stage IV Lung Cancer
With:A Q&A with David Spigel, MD, Chief Scientific Officer, Director of the Lung Cancer Research Program, and Principal Investigator at Sarah Cannon Research Institute. Email: dspigel@tnonc.com Q: You are an expert medical oncologist with particular interest in lung cancer. The various forms of lung cancer are serious diagnoses, all potentially lethal malignancies. There are theoretical, investigational, and clinical justifications to perform molecular testing of… Read more »
-
February 11, 2020
The Evolutionary History of 2,658 Cancers Bookmark
George Lundberg, MDResearch paper from Nature curated by Editor in Chief George Lundberg, MD, who notes:
A massive study of thousands of cancers that explores the genomic basis for cancer is being reported simultaneously in dozens of journals. Nature has published this summary article.
Go to full paper published in Nature.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
February 11, 2020
Carcinoma of Unknown Primary Case Reviewed in Tumor Board Session Bookmark
George Lundberg, MDArticle from CAP Today curated by Editor in Chief George Lundberg, MD, who notes:
Tumor boards are an established method of dealing with problem cancer cases. In precision oncology, they may, even must, be molecular. This is a great example of how a molecular tumor board can provide actionable insights for patients.
Go to full article published by CAP Today.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
January 6, 2020
Clinical Parameters Outperform Molecular Subtypes for Predicting Outcome in Bladder Cancer: Results from Multiple Cohorts, Including TCGA Bookmark
George Lundberg, MDResearch paper from The Journal of Urology curated by Editor in Chief George Lundberg, MD, who notes:
In this study, clinical and basic pathologic findings outperformed molecular typing in predicting outcomes of bladder cancer.
Go to full paper published in The Journal of Urology.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 13, 2019
A Virtual Molecular Tumor Board to Improve Efficiency and Scalability of Delivering Precision Oncology to Physicians and Their Patients Bookmark
George Lundberg, MDResearch paper from JAMIA Open curated by Editor in Chief George Lundberg, MD, who notes:
This study found a virtual molecular tumor board to be efficient and effective for more than 1,000 patients.
Go to full paper published in JAMIA Open.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
November 4, 2019
Using Molecular Testing to Guide Treatment for Advanced Colorectal Cancer
With:A Q&A with Kalpana Kannan, PhD, former Scientist at Cancer Commons Q: Colorectal cancer is common, and although many cases in earlier stages are cured by surgery alone or with adjuvant chemotherapy, it is still a lethal threat for many patients. Nonetheless, several new targeted and immunotherapeutic agents are now available. When should patients receive molecular testing for their colorectal cancer, what information should… Read more »
-
October 1, 2019
Diagnostic Testing for Diffuse Gliomas Bookmark
George Lundberg, MDAnnouncement from the College of American Pathologists curated by Editor in Chief George Lundberg, MD, who notes:
What forms of testing should be done for diffuse gliomas? In this announcement, a global panel invites comments about proposals.
Go to full announcement published by the College of American Pathologists.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.